Análisis de la acción Pelthos Therapeutics Inc (PTHS)

Análisis de IA of Pelthos Therapeutics Inc (PTHS)

Mantener

Pelthos Therapeutics Inc is not a strong buy at the moment due to its current price of $11.52, which is significantly below its 52-week high of $37.50. The RSI is at 31.083, indicating that the stock is oversold, but the recent performance shows a 5-day change of -24.21% and a year-to-date change of -60.88%. While there are positive catalysts such as revenue growth to $10.7 million in Q1 2026 and a strategic merger with Castle Creek, the company still faces significant financial challenges, including a net loss of $10.2 million in Q1 and a forward P/E ratio of 0, suggesting uncertainty in profitability. The main risk is the high volatility in prescription trends for its lead product ZELSUVMI, which analysts have noted as flat. Therefore, while there may be potential for recovery, the current financial instability and market conditions suggest a cautious approach.

Métricas de valoración

El PER previsto actual de Pelthos Therapeutics Inc (PTHS) es 0.00, frente a su media de 5 años de -7.52.

PER previsto

Sobrevalorado

Media 5A P/E

-7.52

P/E actual

0.00

Sobrevalorada

-2.80

Infravalorada

-12.25

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-1.03

EV/EBITDA actual

-0.81

Sobrevalorada

0.01

Infravalorada

-2.07

Precio/ventas previsto

Valor razonable

Media 5A P/S

1.33

P/S actual

0.34

Sobrevalorada

2.65

Infravalorada

0.01

Escenarios de precio de Alphio AI para PTHS

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%PTHS

$26.27

Precio del escenario

B

Base

Base · 50%PTHS

$23.56

Precio del escenario

B

Bajista

Bajista · 25%PTHS

$23.29

Precio del escenario

Preguntas frecuentes sobre PTHS, respondidas por Alphio AI

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older. It operates in the Healthcare sector.

Pelthos Therapeutics Inc is not a strong buy at the moment due to its current price of $11.52, which is significantly below its 52-week high of $37.50. The RSI is at 31.083, indicating that the stock is oversold, but the recent performance shows a 5-day change of -24.21% and a year-to-date change of -60.88%. While there are positive catalysts such as revenue growth to $10.7 million in Q1 2026 and a strategic merger with Castle Creek, the company still faces significant financial challenges, including a net loss of $10.2 million in Q1 and a forward P/E ratio of 0, suggesting uncertainty in profitability. The main risk is the high volatility in prescription trends for its lead product ZELSUVMI, which analysts have noted as flat. Therefore, while there may be potential for recovery, the current financial instability and market conditions suggest a cautious approach.